Skip to main content
Glama

Arcgis Kansas

by io.github.pipeworx-io

Resolve Entity

resolve_entity
Read-onlyIdempotent

"What's the ticker for…" / "find the CIK for…" / "what's the LEI for…" / "what's the RxCUI for…" / "look up the ID for…" / "what is X's official identifier" / "who owns X" / "is X a subsidiary of Y" — resolve a user-spoken NAME to the canonical/official identifiers other tools require as input. Use FIRST whenever you have a name but need an ID. SUPPORTED TYPES: "company" (cross-source identity spine: 10-digit CIK + ticker + company_name from SEC EDGAR, legal-entity LEI from GLEIF with parent/ultimate-parent/children ownership when the LEI resolves, and security FIGI from OpenFIGI — by exact ticker map when a ticker is implied, and otherwise by name search, so NON-EQUITY instruments that never have a ticker (municipal and corporate bonds, notes, authority debt) DO resolve here; when a name matches more than one instrument it asserts nothing and returns figi_candidates to pick from, which is the correct answer to an issuer name that does not identify a single bond; every identifier is labelled with the source that established it, and an identifier that could NOT be resolved is stated explicitly under unresolved rather than omitted — accepts ticker, CIK, ISIN, or company name as input; an ISIN like "CH0038863350" resolves to the LEGAL ENTITY that issued the security via the GLEIF ISIN-to-LEI mapping, covering non-US issuers EDGAR cannot reach), "drug" (returns RxCUI + ingredient + brand from RxNorm + pipeworx://rxnorm/concept/{rxcui} citation; accepts brand or generic name). LEI/FIGI enrichment degrades gracefully — if GLEIF or OpenFIGI is unavailable, the EDGAR identifiers still return. Each call cascades through several lookup endpoints internally — using resolve_entity replaces 2-3 manual lookups.

Input Schema

TableJSON Schema
NameRequiredDescriptionDefault
typeYesEntity type: "company" or "drug".
valueYesFor company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., "ozempic", "metformin"). Pass the ENTITY NAME ONLY — for a bond that is the ISSUER exactly as printed ("NEW YORK ST DORM AUTH"), never the question's full noun phrase ("NEW YORK ST DORM AUTH revenue bonds"): the FIGI lookup matches instrument names, so trailing security-class words match nothing.

Schema Changelog

Changes observed during successful MCP inspections. Dates show when Glama detected each change.

  1. Changed1 schema field changed
    • changedInput schema / properties / value / description
      Previous value: -"For company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., \"ozempic\", \"metformin\")."New value: +"For company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., \"ozempic\", \"metformin\"). Pass the ENTITY NAME ONLY — for a bond that is the ISSUER exactly as printed (\"NEW YORK ST DORM AUTH\"), never the question's full noun phrase (\"NEW YORK ST DORM AUTH revenue bonds\"): the FIGI lookup matches instrument names, so trailing security-class words match nothing."
  2. First observed

TDQS

A4.7/5.0
Behavior5/5

Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?

Beyond annotations that mark the tool read-only and idempotent, the description discloses meaningful behaviors: graceful degradation when GLEIF/OpenFIGI are unavailable, ambiguous-name handling via figi_candidates, explicit reporting of unresolved identifiers, source-labelling, and internal multi-endpoint cascading. No contradiction with annotations exists.

Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.

Conciseness4/5

Is the description appropriately sized, front-loaded, and free of redundancy?

The description is front-loaded with user-like examples and an explicit 'Use FIRST' directive. It is dense and contains long parenthetical asides, but nearly every clause adds necessary behavioral or semantic detail, so the length is justified even if not perfectly concise.

Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.

Completeness5/5

Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?

There is no output schema, so the description compensates by explaining what identifiers are returned, how ambiguity is represented, what happens when external sources fail, and what input formats are accepted. An agent has enough information to invoke the tool correctly and interpret its likely results.

Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.

Parameters5/5

Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?

Although schema coverage is 100%, the description significantly enriches parameter meaning: 'company' resolves across EDGAR/GLEIF/OpenFIGI, 'drug' maps to RxNorm RxCUI, ISIN inputs resolve to legal entities via LEI, and value guidance explains why only the issuer name should be passed for bonds. These details go well beyond the schema's basic descriptions.

Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.

Purpose5/5

Does the description clearly state what the tool does and how it differs from similar tools?

The description defines a specific action—resolving a user-spoken name to canonical/official identifiers—and lists the concrete outputs (CIK, ticker, LEI, FIGI, RxCUI). It also distinguishes the tool from siblings by positioning it as the first lookup when an ID is needed, rather than a profiling or comparison tool.

Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.

Usage Guidelines4/5

Does the description explain when to use this tool, when not to, or what alternatives exist?

The description gives an explicit trigger: 'Use FIRST whenever you have a name but need an ID.' It also covers important sub-cases like bonds and drugs. However, it does not explicitly state when not to use this tool or name a specific alternative, so it falls slightly short of a complete routing rule.

Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.

All Arcgis Kansas toolsInspect
Try in Browser
RayrunBuild, deploy, and operate MCP servers without becoming an infrastructure team.ray.runAd

Glama MCP Gateway

Add one secure layer between your agents and this server.

TDQS

A3.5/5.0
Disambiguation1/5

Many tools have overlapping purposes (e.g., ask_pipeworx, ask_pipeworx_beta, ask_pipeworx_grounded all route questions; polymarket_arbitrage, polymarket_edges, polymarket_edge_tracker all deal with prediction market edges). The inclusion of memory tools (remember, recall, forget) alongside research tools further blurs boundaries.

Naming Consistency2/5

Naming conventions are mixed: some tools use snake_case (ai_visibility_check), some use underscores with prefixes (ask_pipeworx, polymarket_arbitrage), and others are more generic (query_layer, layer_info). There is no consistent pattern across the set.

Tool Count2/5

With 34 tools, the set is overly large for a geospatial server; most tools are unrelated to ArcGIS Kansas (e.g., prediction market tools, general research tools). Only 3 tools (search_datasets, layer_info, query_layer) are pertinent, making the count excessive and unfocused.

Completeness1/5

The server claims to be an ArcGIS Kansas tool but provides only basic layer querying and dataset search. Missing essential GIS operations such as editing, spatial analysis, or advanced queries, making it severely incomplete for its stated purpose.

Resources